TLDR: 21Shares filed a new INJ ETF, joining Canary and Rex Osprey ETFs in progress for the token. Injective’s 24-hour trading volume rose 5.4%, hitting $79.4 million, showing increased market activity. INJ price ranged from $7.81 to $10.04 over the past week, currently trading at $8.80. Staking activity continues to climb as holders maintain positions [...] The post 21Shares Files New INJ ETF as Institutional Interest Surges in Injective appeared first on Blockonomi.TLDR: 21Shares filed a new INJ ETF, joining Canary and Rex Osprey ETFs in progress for the token. Injective’s 24-hour trading volume rose 5.4%, hitting $79.4 million, showing increased market activity. INJ price ranged from $7.81 to $10.04 over the past week, currently trading at $8.80. Staking activity continues to climb as holders maintain positions [...] The post 21Shares Files New INJ ETF as Institutional Interest Surges in Injective appeared first on Blockonomi.

21Shares Files New INJ ETF as Institutional Interest Surges in Injective

2025/10/21 05:04

TLDR:

  • 21Shares filed a new INJ ETF, joining Canary and Rex Osprey ETFs in progress for the token.
  • Injective’s 24-hour trading volume rose 5.4%, hitting $79.4 million, showing increased market activity.
  • INJ price ranged from $7.81 to $10.04 over the past week, currently trading at $8.80.
  • Staking activity continues to climb as holders maintain positions despite recent market declines.

Injective (INJ) is attracting growing attention from institutional investors after 21Shares filed a new ETF for the token. 

The filing marks INJ as one of the few digital assets with multiple ETF products in progress. Market activity for Injective is also rising, with trading volume increasing over the past 24 hours. 

Staking participation remains strong even after price dips, signaling steady confidence among holders. Tweets from the crypto community confirm that institutional and retail participants are closely watching the asset’s development.

Institutional ETF Interest Drives $INJ Market Focus

21Shares’ latest filing positions Injective alongside Canary and Rex Osprey ETFs, reinforcing the token’s appeal to large investors. 

Injective reported a 24-hour trading volume of $79,488,333, a 5.4% increase from the previous day, according to CoinGecko. 

Crypto commentator John_dgreatestt noted that multiple ETF filings reflect growing trust in INJ by institutional players. Increased liquidity could help Injective gain mainstream recognition as market participants pay closer attention to price movements.

Institutional involvement also signals potential changes in trading patterns for the token. 

Gemtoast highlighted that INJ staking activity is rising daily. Investors continue holding their positions despite recent price corrections, suggesting confidence in the long-term outlook. 

Analysts note that such developments could stabilize market sentiment while encouraging further adoption among institutional funds.

Injective Price Trends and Market Activity

Injective’s price fluctuated between $7.81 and $10.04 over the last week, closing at $8.80 during the latest trading session. 

The token gained 1.75% in the past 24 hours while maintaining higher trading activity than the previous day. These movements such as ETFs often create increased demand for the underlying asset. 

Community discussions emphasize that rising staking numbers demonstrate a committed user base supporting Injective’s ecosystem.

Price data combined with rising ETF interest could signal new trading dynamics. Institutional filings often drive short-term liquidity spikes while encouraging holders to stake or increase exposure. 

Tweets from the community reinforce that investors are actively monitoring both price and adoption metrics. Market participants now weigh staking activity alongside potential ETF inflows when evaluating $INJ performance.

The post 21Shares Files New INJ ETF as Institutional Interest Surges in Injective appeared first on Blockonomi.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Share Insights

You May Also Like

House Judiciary Rejects Vote To Subpoena Banks CEOs For Epstein Case

House Judiciary Rejects Vote To Subpoena Banks CEOs For Epstein Case

The post House Judiciary Rejects Vote To Subpoena Banks CEOs For Epstein Case appeared on BitcoinEthereumNews.com. Topline House Judiciary Committee Republicans blocked a Democrat effort Wednesday to subpoena a group of major banks as part of a renewed investigation into late sex offender Jeffrey Epstein’s financial ties. Congressman Jim Jordan, R-OH, is the chairman of the committee. (Photo by Nathan Posner/Anadolu via Getty Images) Anadolu via Getty Images Key Facts A near party-line vote squashed the effort to vote on a subpoena, with Rep. Thomas Massie, R-Ky., who is leading a separate effort to force the Justice Department to release more Epstein case materials, voting alongside Democrats. The vote, if successful, would have resulted in the issuing of subpoenas to JPMorgan Chase CEO Jamie Dimon, Bank of America CEO Brian Moynihan, Deutsche Bank CEO Christian Sewing and Bank of New York Mellon CEO Robin Vince. The subpoenas would have specifically looked into multiple reports that claimed the four banks flagged $1.5 billion in suspicious transactions linked to Epstein. The failed effort from Democrats followed an FBI oversight hearing in which agency director Kash Patel misleadingly claimed the FBI cannot release many of the files it has on Epstein. Get Forbes Breaking News Text Alerts: We’re launching text message alerts so you’ll always know the biggest stories shaping the day’s headlines. Text “Alerts” to (201) 335-0739 or sign up here. Crucial Quote Dimon, who attended a lunch with Senate Republicans before the vote, according to Politico, told reporters, “We regret any association with that man at all. And, of course, if it’s a legal requirement, we would conform to it. We have no issue with that.” Chief Critic “Republicans had the chance to subpoena the CEOs of JPMorgan, Bank of America, Deutsche Bank, and Bank of New York Mellon to expose Epstein’s money trail,” the House Judiciary Democrats said in a tweet. “Instead, they tried to bury…
Share
2025/09/18 08:02
Share